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The management of locally advanced or recurrent extremity sarcoma often necessitates multimodal therapy to preserve a
limb, of which isolated limb perfusion (ILP) is a key component. However, with standard chemotherapeutic agents used in ILP,
the duration of response is limited. Novel agents or treatment combinations are urgently needed to improve outcomes. Previ-
ous work in an animal model has demonstrated the efficacy of oncolytic virotherapy when delivered by ILP and, in this study,
we report further improvements from combining ILP-delivered oncolytic virotherapy with radiation and surgical resection. In
vitro, the combination of radiation with an oncolytic vaccinia virus (GLV-1h68) and melphalan demonstrated increased cytotox-
icity in a panel of sarcoma cell lines. The effects were mediated through activation of the intrinsic apoptotic pathway. In vivo,
combinations of radiation, oncolytic virotherapy and standard ILP resulted in delayed tumour growth and prolonged survival
when compared with standard ILP alone. However, local disease control could only be secured when such treatment was com-
bined with surgical resection, the timing of which was crucial in determining outcome. Combinations of oncolytic virotherapy
with surgical resection and radiation have direct clinical relevance in extremity sarcoma and represent an exciting prospect for
improving outcomes in this pathology.
The management of locally advanced or recurrent extremity
soft tissue sarcoma (ESTS) is extremely challenging. As ampu-
tation has not been shown to improve survival, the goal of
treatment in such cases is to secure local disease control and
preserve limb function.1–3 Isolated limb perfusion (ILP) is a
specialised surgical technique that forms a key component of
the multimodal management of such patients. In the presence
of a large, locally advanced ESTS that risks signiﬁcant func-
tional morbidity with resection, ILP may be used as a neoadju-
vant therapy to downsize the tumour before surgical
resection.4 If a tumour is truly inoperable by any means other
than amputation, ILP is an alternative palliative option allow-
ing symptom control and preservation of limb function.5
Using the standard protocol with melphalan and tumour
necrosis factor a (TNF-a), approximately 60% of patients have
a signiﬁcant response to ILP.6 Although some patients may
beneﬁt with long-standing disease control, the response to ILP
alone is short-lived in the majority of cases with disease pro-
gression occurring within 12 months.7 Furthermore, the effects
are limited to the perfusion ﬁeld and have no signiﬁcant
impact on the dissemination of disease or overall survival.8
There is a clear need to improve outcomes in this challenging
group of patients, either through the use of novel agents or the
development of alternative treatment combinations.
With this aim in mind, an orthotopic model of ESTS and
ILP has been developed.9 Oncolytic virotherapy was identiﬁed
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as a potential therapy for combination with ILP. Oncolytic
virotherapy has been shown to be clinically effective when
delivered by intra-tumoural injection.10 However, the sys-
temic administration of oncolytic virotherapy is hampered by
sequestration within the reticulo-endothelial system, clearance
by circulating antibodies and an inability to penetrate the
tumour in sufﬁcient titres.11 Due to its ability to target the
delivery of therapy directly to the tumour whilst affording
protection from viral sequestration, ILP was thought to be
ideally suited to combination with oncolytic virotherapy. This
was conﬁrmed in an in vivo model, where the addition of an
oncolytic vaccinia virus (GLV-1h68)12 to the standard ILP
protocol, resulted in delayed tumour growth and prolonged
survival.9 However, local disease control was not achieved
and modiﬁcations to this treatment regimen were explored.
Radiotherapy has a well-established role in securing local
disease control following resection of ESTS.2,13 Radiotherapy
may also be used following an inadequate response to neoad-
juvant ILP.14 Therefore, the combination of oncolytic viro-
therapy delivered by ILP and radiotherapy is a treatment
regimen that may be readily translated into clinical practice.
Furthermore, ionising radiation has been shown to be syner-
gistic with oncolytic virotherapy in preclinical models of mel-
anoma, glioma and head and neck cancers.15–19
In these studies, we investigated the efﬁcacy of combining
oncolytic virotherapy delivered by ILP with radiation and
surgery to determine if this regimen can be exploited in the
clinic to improve clinical outcomes in ESTS.
Material and Methods
In vitro studies
Cell lines. The BN175 rat sarcoma cell line was kindly
donated by Prof. A Eggermont. This cell line is tumorigenic in
Brown Norway rats.20 The CV1 monkey kidney cell line was
obtained from existing laboratory stocks. The HT1080, SW684
and SW872 human sarcoma cell lines were donated by Dr.
Janet Shipley. Cells were passaged in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM), supplemented with 5–10% heat-
inactivated foetal bovine serum (FBS), 2.5% L-glutamine and
1% penicillin/streptomycin. Cells were cultured at 378C in an
incubator maintaining a 10% carbon dioxide atmosphere.
Cytotoxic agents. GLV-1h68 was produced and provided by
Genelux Corporation (San Diego). GLV-1h68 is an attenu-
ated vaccinia virus strain and was constructed as previously
described.12
Melphalan (Alkeran; Laboratoires Genopharm, France).
Melphalan was supplied as a powder. Prior to injection it
was dissolved in a diluent composed of water, sodium citrate,
propylene glycol and ethanol, to a concentration of 1 mg/mL.
Recombinant human Tumour Necrosis Factor alpha was
supplied as a lyophilised powder (First Link Ltd, Birmingham,
UK) and was dissolved in PBS and stored at 2208C until use.
External beam radiotherapy. All in vitro and in vivo irradia-
tions were performed using an orthovoltage X-ray source
(320/250 kV; serial no: 200090606; AGO X-Ray Ltd, Reading,
UK). The dose of radiation delivered was calculated with a
universal dosimeter (UNIDOSE Universal Dosimeter, PTW,
Grantham, UK).
LacZ detection. HT1080, SW684, SW872 and BN175 cells
were plated at a density of 1 3 105 per well in 24-well plates.
After incubation at 378C for 16 hr, plates were treated with
GLV-1h68 at a MOI of 0.1. At speciﬁed time points, cells
were ﬁxed with 2% formaldehyde/0.2% glutaraldehyde then
stained for 4 hr with X-Gal staining buffer and X-Gal (Cal-
BioChem, Merck KGaA, Germany; 1:100) then washed with
ultraﬁltered water and dried.
Sulphorhodamine B assay. BN175 cells were plated at a
density of 5 3 104 cells per well in a 24-well plate. After 16
hr cells were treated with either GLV-1h68 MOI 0.01, mel-
phalan 250 nM or both. After six hours, cells were irradiated
at 0, 2, 4 or 8 Gy and then incubated at 378C for 72 hr. Cell
viability was quantiﬁed by ﬁxing with 10% trichloroacetic
acid (Sigma Aldrich, UK) and then staining with sulphorhod-
amine B (SRB; Sigma Aldrich, UK). The stained cells were
dissolved with 1 mM TRIS (Sigma Aldrich, UK) and absorb-
ance was measured at 570 nm on a plate reader (Victor 2,
Perkin Elmer, MA).
Western blot analysis. Cells were plated at 5 3 105 cells in
60 mm dishes. Following various treatments, cells were har-
vested after 48 hr in ice-cold phosphate-buffered saline (PBS),
pelleted and resuspended in radioimmunoprecipitation assay
buffer (50 mM Tris (pH 7.5), 150 mM NaCl, 1% NP40, 0.5%
sodium deoxycholate and 0.1% SDS) with protease inhibitors
(Roche Diagnostics Gmbh, Mannheim, Germany), 1 mM
sodium orthovanadate (Sigma Aldrich, Gillingham, UK) and
What’s new?
The management of locally advanced or recurrent extremity sarcoma often necessitates multimodal therapy to preserve a
limb, of which isolated limb perfusion (ILP) is a key component. But the response to standard ILP is short-lived in the majority
of cases, making novel agents or treatment combinations urgently needed. Previous work in an animal model has demon-
strated the effectiveness of combining oncolytic virotherapy with ILP. However, local disease progression was delayed rather
than prevented. This paper demonstrates that durable local disease control can be achieved when ILP-delivered oncolytic viro-
therapy is utilised as an induction therapy prior to surgical resection and radiotherapy.
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10 mM sodium ﬂuoride. Cells were then lysed by snap freezing
on dry ice and allowed to thaw on ice for 10 min. The lysate
was then centrifuged at 13,200 rpm at 48C for 20 min to
remove cell debris. Protein concentration was determined
using the BCA protein assay (Pierce, Rockford, IL). Then 30 lg
of each protein sample were resolved on SDS-polyacrylamide
gels (10–12%) and transferred to a polyvinylidene diﬂuoride
Hybond-P membrane. Immunodetections were performed
using procaspase and cleaved caspase 3 (Cell Signalling) rabbit
polyclonal antibody in conjunction with a horseradish peroxi-
dase (HRP)-conjugated anti-rabbit secondary antibody (GE
Healthcare). Equal loading was assessed using glyceraldehyde-
3-phosphate dehydrogenase-GAPDH (Cell Signalling). The
Super Signal chemiluminescent system (Pierce, Rockford, IL)
or Immobilon Western chemiluminescent HRP substrate
(Millipore) were used for detection.
Caspase-Glo assay. The Caspase-Glo 3/7 Assay (Promega)
was used to determine the relative levels of Caspase 3/7 acti-
vation 48 hr postinfection with GLV-1h68 (MOI 0.1), 1/2
melphalan 250 nM, 1/2 radiation (2 or 4 Gy) according to
the manufacturer’s instructions. Detected levels were normal-
ised according to the proportion of surviving cells, as deter-
mined by duplicate MTT assay carried out simultaneously.
In vivo studies
Animals. Inbred, speciﬁc pathogen-free adult male Brown
Norway rats weighing between 225 and 275 g were obtained
from Charles River (Margate, UK) or Harlan (Nottingham,
UK). They were housed in compliance with all relevant regula-
tory requirements and fed standard chow and water ad
libitum.
Orthotopic model of advanced extremity sarcoma. The
orthotopic model of extremity sarcoma was used as previously
described.9 Tumour growth was assessed every 48 hr by direct
calliper measurement in two orthogonal dimensions. Tumour
volume was calculated using the formula: Volume5 1=2
(width2 3 breadth). Animals were culled at an agreed humane
endpoint of 2 cm maximum tumour diameter.
Isolated limb perfusion: Operative technique. Cohorts were
treated on Day 6 postengraftment of 1 3 107 BN175 cells
into the left hind limb, with a median tumour size of
1.4 cm3. The control group underwent a surgical procedure
under general anaesthetic with open ligation of the left super-
ﬁcial femoral artery and vein using 5/0 ethilon. For the treat-
ment cohorts, an ILP was performed on Day 6 as previously
described.9 In brief, under general anaesthesia, a 1-cm inci-
sion was made over the left groin crease. Using an operative
microscope, the femoral vessels, nerve and inguinal ligament
were visualised and exposed. The superﬁcial femoral artery
and vein were ligated proximally and controlled distally using
5/0 ethilon. A venotomy was then made and the vein cannu-
lated. Twenty units of heparin in 2 mL of 0.9% saline were
then injected into the vein allowing systemic circulation and
anticoagulation. An arteriotomy was then made and the
artery cannulated and connected to a perfusion pump using
silicone tubing primed with 0.9% saline. An elastic band was
used as a tourniquet, applied tightly to the left hind limb
proximal to the cannulation site. The perfusion circuit was
brought into continuity with the perfusate reservoir (contain-
ing 8 mL haemaccel, bubble oxygen and heated to 398C) and
a perfusion established through the hind limb at a ﬂow rate
of 4 mL/min. Once a stable perfusion was conﬁrmed the
Figure 1. ILP perfusion circuit. (a) Cartoon schematic demonstrating the ILP perfusion circuit, using an oxygenated, hyperthermic perfusion
reservoir into which the investigational therapeutic agents are added and (b) photograph of a Brown Norway rat undergoing ILP. [Color fig-
ure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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required therapeutics were added to the perfusate (GLV-1h68
1 3 107 pfu, melphalan 100 lg, TNF-a 50 lg) and the limb
perfused for 13 min. The circuit was then washed out using
0.9% saline for 2 min. The tourniquet was then released and
the artery and vein ligated distal to the cannulation site. The
skin was then closed with 6/0 vicryl rapide and the operative
site cleaned (Figs. 1a and 1b).
External beam radiotherapy. Therapeutic irradiations were
performed under general anaesthesia using an intraperitoneal
injection of 1.5–3 mL/kg of a 1:1:2 solution of Hypnorm
(Janssen Pharmaceutical Ltd., UK), Hypnovel (Roche, UK)
and sterile water. Anaesthetised animals were placed in a
custom-made 6 mm lead shield. The shield abducts the leg
from the midline, such that the tumour may be irradiated
through a window, whilst minimising irradiation of the surgi-
cal wound, abdominal viscera or other structures.
Surgical resection of tumours. Two therapeutic regimens
combining ILP (melphalan, TNF-a and GLV-1h68) with irra-
diation (13 Gy in 2 fractions) and surgical resection were
used. At either Day 3 or Day 10 postILP, surgical resection
of the tumour was carried out under general anaesthetic. An
elliptical incision was made in the skin over the palpable sur-
face of the tumour. Adherent subcutaneous tissue and fascia
was resected en-bloc with the tumour. All visible tumour was
removed as a single specimen without tumour rupture. At
the deep margin of the tumour, the ﬁbula and peroneal bun-
dle were preserved to maintain limb function. The fascia and
skin were closed in separate layers with 6/0 vicryl rapide.
Statistical analysis
Simple and descriptive analyses were performed using Micro-
soft Excel (Microsoft Inc, WA). Kaplan–Meier survival analy-
sis and group analysis, including ANOVA, were performed
using GraphPad Prism software (GraphPad Software Inc,
CA). Statistical signiﬁcance was deﬁned as a p values of less
than 0.05. Error bars on all graphs represent standard error
of the mean.
Figure 2. The combination of GLV-1h68, melphalan and radiotherapy activates the effector caspase pathway and significantly increases
cytotoxicity. (a) Microscopic image of GLV-1h68 infection and LacZ transgene expression in a panel of rat and human sarcoma cell lines at
increasing time points postinfection with GLV-1h68 (MOI 1). (b) SRB assay showing increased cytotoxicity with triple combination therapy
at 72 hr post-treatment with GLV-1h68 (MOI 0.01), melphalan (250 nM) and EBRT. This is statistically significant between 0 and 8 Gy for
the control, GLV-1h68 and melphalan-treated cells and between 0 to 4 Gy and 0–8 Gy in the combination therapy (GLV-1h68 and melpha-
lan) cohort. (c) Induction of caspase 3 cleavage on western blot analysis and (d) Caspase–Glo assay showing quantitative analysis of
caspase 3 and 7 production at 48 hr post-treatment. With 0 and 2 Gy of EBRT, this is statistically significant between the control and
melphalan and the control and combination therapy (GLV-1h68 and melphalan) group. At 4 Gy statistical significance is only seen between
the control and combination therapy group. (C5 control, M5melphalan and VV5GLV-1h68) (*5 p values <0.01, **5 p values <0.01 and
**5 p values <0.01). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Results
GLV-1h68 readily infects and replicates within rodent and
human sarcoma cell lines
The ability of GLV-1h68 to infect and replicate within sarcoma
cell lines was investigated by observing the number of cells
expressing the GLV-1h68 LacZ transgene product, b-
galactosidase, at successive time-points. The BN175 rat ﬁbrosar-
coma cell line and a panel of human sarcoma cell lines com-
prising SW872 (liposarcoma), SW684 (ﬁbrosarcoma) and
HT1080 (ﬁbrosarcoma) were tested. At 6, 12 and 24 hr post-
treatment with GLV 1h68 (MOI 1.0), cells were ﬁxed and
then stained for b-galactosidase. Viral transgene expression
was detectable as early as 6 hr postinfection in all cell lines.
LacZ expression increased over the observed time period with
almost complete infection of all cells, in all cell lines by 24 hr
(Fig. 2a).
The cytotoxic effect of combination therapy with GLV-1h68
and melphalan is significantly enhanced with the addition
of ionizing radiation
The cytotoxic effects of combination therapy with GLV-1h68
(MOI 0.1), melphalan (250 nM) and external beam radio-
therapy (EBRT; 2, 4 and 8 Gy) were investigated using an
SRB assay. When compared with either modality alone, the
addition of radiation to melphalan or GLV-1h68 only
increased cytotoxicity at a dose of 8 Gy. A statistically signiﬁ-
cant increase in cytotoxicity was demonstrated with triple
therapy compared to GLV-1h68 combined with melphalan
alone at doses of 4 and 8 Gy (Two-way ANOVA with
Bonferroni post-test; p< 0.01; Fig. 2b).
Treatment with GLV-1h68, melphalan and EBRT results in
caspase-3 cleavage and apoptotic cell death
At 48 hr, caspase cleavage was not induced by single agent
therapy with GLV-1h68 or melphalan. Low levels of cas-
pase cleavage were induced by EBRT alone at a dose of 4
Gy. However, the combinations of melphalan and GLV-
1h68, GLV-1h68 and EBRT or melphalan and EBRT
resulted in greater cleavage of caspase-3. This was markedly
increased with triple combination therapy (GLV-1h68, mel-
phalan and EBRT) compared to double therapy at both 2
and 4 Gy (Fig. 2c).
This increase in effector caspase-3 and -7 was conﬁrmed
and quantiﬁed using a Caspase Glo assay. The combination
of GLV-1h68 and melphalan caused a signiﬁcant increase in
cleaved caspase 3/7 activity compared to controls at all doses
of radiation (zero, 2 and 4 Gy; p< 0.01) and was superior to
GLV-1h68 alone and GLV-1h68 with 2 Gy (two-way
ANOVA with Bonferroni post-test; p< 0.05). These results
suggest the primary mechanism of cell death is mediated
through the apoptotic signalling pathway (Fig. 2d).
Figure 3. The addition of GLV-1h68 and EBRT to standard ILP delays tumour growth and time to humane end-point. Survival and tumour
growth of animals, bearing BN175 tumours on the left hind limb, after differing treatment regimens. (a) Kaplan–Meier curve of treatment
cohorts; time to humane endpoint. (b) Table of median time to humane endpoint in each cohort. (c) Table displaying surviving number of
animals in each cohort at progressive time points. (d) Photographs of two separate animals showing maximum response to therapy at Day
6 post-treatment with ILP (melphalan, TNF1GLV-1h68)1 EBRT and multifocal tumour relapse at day 16. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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Figure 4. (a & b) Treatment regimens tested for ILP (melphalan, TNF-a and GLV-1h68), EBRT (13 Gy/2 fractions) and surgical resection.
Tumours were measured by external caliper assessment every 2–3 days and the animals culled once tumours reached the maximum limit
of 2 cm. (c) Photographs of an animal (S1), undergoing a marginal tumour resection according to the regimen described in 4A. [Color figure
can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 5. The combination of ILP with melphalan (M), TNF (T) and GLV-1h68 (VV) as neoadjuvant chemotherapy prior to surgical resection
and adjuvant EBRT significantly delays tumour growth and time to humane end-point. (a) Tumour growth delay curve of Brown Norway rats,
bearing BN175 tumours on the left hind limb, after differing treatment regimens. (b) Table of median time to humane endpoint in each
cohort. (c) Kaplan–Meier curve of treatment cohorts; time to humane endpoint. [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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The addition of GLV-1h68 and EBRT to standard ILP delays
tumour growth and prolongs survival in vivo
The therapeutic efﬁcacy of a standard ILP (melphalan and
TNF-a), triple therapy ILP (melphalan, TNF-a and GLV-
1h68) and their combinations with EBRT (13 Gy in 2 frac-
tions) was studied.
The addition of EBRT after standard ILP therapy
resulted in an increase in median survival from 12 days for
controls and 23 days for ILP alone to 35 days. This was
highly statistically signiﬁcant (Log-rank (Mantel-Cox) test;
controls, p5 0.0005; standard ILP, p5 0.0006). The addition
of EBRT to triple therapy ILP (melphalan, TNF-a and
GLV-1h68) resulted in the greatest increase in survival. A
signiﬁcant increase in survival was achieved compared to
standard ILP, from a median of 23–40 days (Log-rank
(Mantel–Cox) test; p< 0.0001). However, when compared
to the combination of EBRT and standard ILP or triple
therapy ILP, no signiﬁcant increase in survival was seen. No
increase in morbidity or mortality was seen in any of the
treatment groups (Figs. 3a–3c).
On visual assessment of the limb and quantitative external
calliper measurement of tumour growth, a consistent maxi-
mum response to therapy was seen at Day 6 postcompletion
of treatment (Day 15 postengraftment of BN175). This
response persisted for a maximum of 10 days prior to the
consistent development of multifocal tumour relapse in the
limb (Fig. 3d).
The timing of surgical resection is critical in producing a
curative treatment regimen when combined with triple
therapy ILP and EBRT
In an attempt to create a curative treatment regimen, two dif-
ferent treatment protocols combining triple therapy ILP with
EBRT and surgical resection were developed (Figs. 4a and
4b). In the ﬁrst protocol, the tumour was resected at the
point of maximal response to ILP and EBRT on Day 16 post-
implantation. The second regimen was developed to reﬂect
clinical practice. ILP is often used as induction chemotherapy
to downsize locally advanced tumours and may be followed
by adjuvant radiotherapy to compromised margins. In this
protocol, the tumour was resected following ILP on Day 9,
with EBRT given one week later.
In the ﬁrst regimen, local disease was controlled for 12
days in 5 of 6 animals and for 21 days in the ﬁnal animal.
All 6 animals developed local disease recurrence. An ulcera-
tive recurrence developed rapidly in 3 animals, requiring the
animals to be culled between 34–45 days postengraftment
prior to reaching the maximum tumour limit of 2 cm (Figs.
5a–5c).
In comparison to triple therapy ILP with EBRT, the addi-
tion of postEBRT surgical resection did not increase survival,
with median survivals of 40 and 38 days, respectively (Log-
rank (Mantel–Cox) test; p5 0.612).
In the second regimen involving early surgery, a signiﬁ-
cant increase in survival was noted compared to the ﬁrst reg-
imen, with a median survival of 70 days (Log-rank (Mantel–
Cox) test; p< 0.001) (Figs. 5–c). Furthermore, 2 of the 6
animals in this group were cured, with no evidence of local
or systemic disease at Day 120 postengraftment of tumour
(Fig. 6a). Following resection, the tumours from all 6 animals
were snap-frozen and homogenised. Viral plaque assays were
used to determine the presence of GLV-1h68. Of the six
tumours, ﬁve were found to have recoverable, replication-
competent virus still present at 72 hr after delivery of virus
by ILP (Fig. 6b).
Local disease control is followed by systemic relapse
Three of the animals in the triple therapy ILP and EBRT
cohort were culled before reaching their humane endpoint
due to lethargy and respiratory distress. At autopsy, macro-
scopic lung metastases were found in all three animals. One
animal also demonstrated inguinal and para-aortic lymph
node metastases. Cell lines were established from the lung
metastases (LM) and para-aortic lymph node (PN). Cell pro-
liferation MTT assays were carried out to deﬁne treatment
sensitivities of these metastatic cell lines to GLV-1h68 and
melphalan. No signiﬁcant difference in sensitivity to these
modalities was noted when compared to the parental BN175
cell line (Supporting Information Fig. 1 a and b). Using clon-
ogenic assays the sensitivity of the metastatic cell lines to
radiation was assessed. Interestingly, both metastatic cell lines
Figure 6. (a) Photographs of the treated limb in the two cured
animals with no evidence of local or systemic recurrence at 120
days post-tumour engraftment and treatment with ILP (melpha-
lan1 TNF-a1GLV-1h68) as induction chemotherapy followed by
surgical resection and adjuvant EBRT. (b) Recovery of GLV-1h68
in tumours 72 hr after ILP. Photograph of plate with viral plaque
assay showing LacZ-expressing live replication-competent virus
recovered from the tumours in five out of the six rats treated
with triple therapy ILP (melphalan, TNF-a and GLV-1h68) 72 hr
before tumour resection. Rat 1 and 3 remained disease free at
120 days postengraftment of tumour. [Color figure can be
viewed in the online issue, which is available at wileyonlineli-
brary.com.]
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were signiﬁcantly less sensitive to radiation at both 4 and 8
Gy (p <0.01, one way ANOVA, Tukey’s post-hoc test).
Discussion
We have developed a rodent model of an aggressive extrem-
ity ﬁbrosarcoma to allow the development and assessment of
novel treatment combinations to optimise tumour control.
This model closely resembles the clinical scenario seen in
many patients with advanced limb sarcomas after treatment
with standard ILP, where an initial local response is followed
by local disease progression that may occur before the devel-
opment of metastatic disease. Using this model, we have pre-
viously shown that the addition of oncolytic virotherapy to
the chemotherapeutic agents currently used in ILP has a syn-
ergistic effect.9 However, long-term local control of the limb
sarcoma was not achieved. We have now modiﬁed this treat-
ment strategy to further improve the efﬁcacy of this approach
and hopefully produce long-term complete responses in the
limb. With this aim in mind, we used oncolytic virotherapy
together with standard ILP chemotherapy but in combination
with surgical resection of the tumour and radiation. The
addition of surgical resection and radiotherapy to ILP is clini-
cally relevant as ILP has been shown to be an effective neo-
adjuvant therapy prior to surgical resection of large, locally
advanced ESTS as a means of allowing limb salvage in what
would be considered normally an irresectable tumour. Fur-
thermore, postoperative radiotherapy may also be used if the
histological response to ILP is inadequate.4,14,21,22
After demonstrating an additive effect in vitro, combina-
tions of oncolytic virotherapy delivered by ILP with radiation
were evaluated in our in vivo model. Although the combina-
tion of radiation with standard ILP chemotherapy (melphalan
and TNFa) improved survival when compared with standard
ILP alone, this combination was no more effective than triple
therapy ILP (melphalan, TNFa and OV). Furthermore, the
addition of radiation to triple therapy ILP conferred no fur-
ther survival beneﬁt. In the absence of a surgical resection,
local disease control in this model could not be achieved.
This scenario closely resembles that seen in clinical practice.
Without surgical resection, the majority of patients with
ESTS treated by ILP develop disease progression within 12
months.7 At this point, further disease progression is
extremely challenging to control with any treatment modality
and many patients proceed to a palliative amputation.5,7
To explore the beneﬁt of surgical resection alongside these
treatments we used two in vivo protocols combining triple
therapy ILP and radiation with surgery. In these protocols all
surgical resections were marginal resections, performed on
the surface of these large tumours and would be classiﬁed
clinically as R1 resections leaving likely microscopic residual
disease in situ.
The ﬁrst protocol was designed to maximise the additive
effects of radiation and oncolytic virotherapy and to allow
time for a viral-mediated anti-tumour immune response to
develop and surgery was deferred until after radiotherapy
had been given. The second protocol was designed to mirror
the normal clinical practice of neoadjuvant ILP followed by a
surgical resection and radiotherapy was administered postop-
eratively to microscopic residual disease. The timing of sur-
gery was found to be critical in producing on-going complete
remissions in the limb, with local disease control only being
achieved with early surgical intervention. There may be sev-
eral reasons for this. Live, replication competent virus was
retrieved from ﬁve of the six tumours resected 72 hr after tri-
ple therapy ILP. Resecting the tumour at this time point may
have enabled the residual virus to control any remaining
microscopic disease, with its therapeutic effect enhanced by
the addition of radiation. A further hypothesis is that with
time, a more heterogeneous tumour cell population develops,
with increased treatment resistance. Early surgical excision
may interrupt this development and improve outcome.
The curative treatment protocol developed in our model
was intensive, although it was well tolerated with no increase
in wound complications or functional morbidity when com-
pared with other cohorts. In clinical practice, the combina-
tion of ILP, surgery and postoperative radiotherapy has been
shown to be associated with poorer wound healing and long-
term functional morbidity in up to two-thirds of patients.23,24
In the presence of an adequate response to ILP, as deter-
mined histologically by the percentage of necrosis of the
specimen, adjuvant radiotherapy has not been shown to be of
further beneﬁt in securing local disease control.25 Therefore,
in order to balance local control with functional morbidity,
adjuvant radiotherapy is now reserved for those patients with
an inadequate response to ILP. Although the data from our
in vivo experiments are encouraging, whether a modiﬁed pro-
tocol with the addition of an oncolytic virus will be as tolera-
ble and as efﬁcacious in the clinic requires clariﬁcation in a
phase I clinical trial.
ESTS comprise a heterogeneous mix of histological sub-
types. A limitation to this study is that only one cell line,
BN175, could be used for in vivo experimentation. In order
to more accurately study the effects of virotherapy, an
immune competent model is desirable and precludes the use
of human xenografts. Although a mouse model of ILP has
been described, this was not found to be reproducible by our
team.26 As such, in vivo experiments were limited to the
BN175 cell line, as it alone was syngeneic in rats. In vitro
experiments provided encouraging data suggesting that this
combination treatment has the potential for clinical transla-
tion. However, these experiments were limited to ﬁbrosar-
coma and liposarcoma lines and whether this approach will
be as effective across a range of histological subtypes remains
to be seen.
With improved local disease control, the metastatic
potential of this tumour model was revealed. This develop-
ment provides a platform for future work aimed at inter-
rupting the metastatic pathway in this model. Oncolytic
virotherapy is increasingly considered as a form of immu-
notherapy. The ability to promote an anti-tumour immune
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response has been demonstrated with several oncolytic
viruses including vaccinia, herpes simplex virus, reovirus,
parvovirus and myxoma virus.10,27–30 Furthermore, there is
evidence to suggest that immune activation rather than
viral replication or oncolysis is key to the tumouricidal
effects of oncolytic virotherapy.31 Although oncolytic vacci-
nia was unable to prevent metastatic disease in our model,
future work will be directed at combining oncolytic viro-
therapy with other immunomodulatory adjuvant therapies
with the aim of preventing and treating metastases. If their
potential were realised, these combinations may provide a
means of engendering a tumour-speciﬁc immune response
prior to the resection of a tumour to safeguard against both
local and distant recurrence.
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